This table shows the list known insiders, and is generated automatically from filings disclosed to the SEC. In addition to the names, most recent title, and director, officer, or 10% owner designation, we provide the latest disclosed holdings.
| Name | Shares | Options |
|---|---|---|
| Longitude Capital Partners III, LLC By Longitude Venture Partners III, L.P. | 4,174,379 | 0 |
| Hopfner Robert Lorne By Pivotal bioVenture Partners Fund I, L.P. | 2,661,154 | 0 |
| Pivotal bioVenture Partners Fund I, L.P. | 2,661,154 | 0 |
| MAKOWER JOSHUA See Note 2 | 2,437,689 | 0 |
| SANDELL SCOTT D See Note 2 | 2,437,689 | 0 |
| Sonsini Peter W. See Note 2 | 2,437,689 | 0 |
| New Enterprise Associates 15, L.P. | 2,437,689 | 0 |
| Makhzoumi Mohamad See Note 2 | 2,437,689 | 0 |
| BASKETT FOREST See Note 2 | 2,437,689 | 0 |
| Florence Anthony A. Jr. See Note 2 | 2,437,689 | 0 |
| Sofinnova Venture Partners X, L.P. | 2,028,308 | 0 |
| RA CAPITAL MANAGEMENT, LLC | 2,003,653 | 0 |
| Rock Springs Capital Management LP | 1,067,884 | 0 |
| Bolte Axel | 258,575 | 0 |
| Bjarke Henric Bjorn | 80,626 | 0 |
| Subramanian Sanjay | 27,100 | 0 |
| Jungles Steven J By Steven Jungles Trust Dated Nov. 12, 2014 | 0 | 0 |
| Mathers Edward T | 0 | 9,367 |
| Bhagat Sarah M | 0 | 9,367 |
| 0 | 0 | |
| DiPalma Stephen J. | 0 | 0 |
| Sullivan Lynne Marie | 0 | 9,367 |
| Wenkert Deborah | 0 | 0 |
| Sanofi Through its wholly-owned subsidiary, Aventis Inc. | 0 | 0 |
| Edwards Martin | 0 | 9,367 |
| Basso Stephen | 0 | 13,000 |
| Schlessinger Joseph | 0 | 0 |
| Hopfner Robert Lorne | 0 | 9,367 |
| Novo A/S | 0 | 0 |
| ALEXION PHARMACEUTICALS INC | 0 | 0 |
| Braddock Demetrios | 0 | 0 |
| Huertas Pedro | 0 | 43,951 |
| Jungles Steven J By Steven Jungles Trust Dated Nov. 12, 2014 | 0 | 0 |
| Inozyme Pharma, Inc. | 0 | 9,367 |
| DIAZ REINALDO M | 0 | 9,367 |
| Treco Douglas A | 0 | 9,367 |
| Jungles Steven J | 0 | 42,000 |
While Insider sales are normal part of tax harvesting and is part of compensation of executives - A large number of transactions would indicate that the management isnt convinced that the price will go up and hence reducing their holding. This would be a possible indicator or fall in price
| Name | Shares | Price | Date |
|---|
Insider buys arent usual, since it indicates a high conviction by the management that they believe the price will go up eventually. Usually a good sign that investors should consider this as a factor to purchase a stock, especially if the current SP is lower than the price the management bought these at. The table below doesnt include any Stock Options or RSUs. They're just open market purchases by the insiders.
| Name | Shares | Price | Date |
|---|---|---|---|
| Longitude Capital Partners III, LLC By Longitude Venture Partners III, L.P. | 1,355,000 | 3.69 | 2022 Apr 19 |
| Pivotal bioVenture Partners Fund I, L.P. | 1,070,000 | 3.69 | 2022 Apr 19 |
| Bjarke Henric Bjorn | 27,100 | 3.69 | 2022 Apr 19 |
| Hopfner Robert Lorne By Pivotal bioVenture Partners Fund I, L.P. | 1,070,000 | 3.69 | 2022 Apr 19 |
| Subramanian Sanjay | 27,100 | 3.69 | 2022 Apr 19 |
| Bolte Axel | 67,750 | 3.69 | 2022 Apr 19 |